Kuros Biosciences is at the forefront of developing innovative biologic fusion technologies aimed at improving spinal fusion outcomes. Their flagship product, MagnetOs, has demonstrated a significantly higher fusion rate compared to traditional autografts in clinical trials, showcasing its effectiveness in addressing the challenges associated with spinal surgeries. The unique NeedleGrip™ surface technology of MagnetOs allows for bone growth even in soft tissues, which contributes to more predictable fusion results. This advancement is particularly crucial given the high failure rates associated with spinal fusions, which currently affect nearly 20% of procedures.

The company emphasizes a strong scientific foundation through its Project Fusion initiative, which integrates extensive scientific, pre-clinical, and clinical research to enhance the quality of spinal surgery. Supported by a strategic advisory board comprising leading spinal surgeons and experts, Kuros Biosciences aims to address the pressing need for reliable bone graft alternatives. Their commitment to research and innovation is evident in their global presence and collaboration with top-tier medical professionals, ensuring that their technologies are backed by robust clinical evidence and expertise in the field of spinal surgery.

Switzerland

Kuros Biosciences is a biotechnology company that specializes in providing superior biologics for better spinal fusions.

Kuros Biosciences

Company Details